What Cigna's David Cordani had to say at a new investor day.
Biotechs are hot.
Time for this one to pop.
Morgan Stanley analyst David Risinger argued for the drugmaker to part ways with its consumer health division.
Massive biotech bet!
The main thrust of the order appears to be easing regulatory hurdles to drug approvals, which could lower the cost of bringing new treatments to market and thus lower prices.
The pharmaceutical company has bought 99% stakes in five coal processing companies since 2011.
Slowing sales and safety concerns have some investors less than enthused, but Amgen says it's drugs in development could deliver.
The FTC is concerned that the Walgreens and Rite Aid deal would result in higher drug prices for consumers.